Status unknownNCT06536933Updated Aug 5, 2024

Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees

An observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-08-05.

Sponsored by Sohag University · Observational

The sponsor has not verified this record recently (last verified Jul 2024), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Case-only
Time perspective: Cross-sectional
Enrollment: 100
Ages: 18 Years to 60 Years
Sex: All

Study summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is a common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality.
The high prevalence of this disease has been fueled by the rapid rise in levels of sedentary behavior, low levels of physical activity, excess calorie intake relative to expenditure in nutritionally imbalanced and unhealthy diets. In parallel, the prevalence of poor metabolic health in adults from many countries is high, even in normal weight individuals.
MASLD has been estimated to affect 30% of the adult population worldwide, with its prevalence increasing from 22% to 37% from 1991 to 2019 . The increasing prevalence of MASLD parallels the increasing prevalence of obesity and obesity-related diseases.

Conditions studied

Metabolic Dysfunction-Associated Steatotic Liver Disease

In context

Lead sponsor

Sohag University is the lead sponsor of 1,220 studies on the registry; 629 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 60 Years
Sexes eligible: All
Sampling method: Probability sample

Study population

100 Employees in Sohag University will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

100 Employees in Sohag University will be included in the study.

Exclusion criteria

Exclusion Criteria:

Employees with drug induced liver disease. Employees with chronic liver disease. Employees with decompensated liver cirrhosis. Employees with excessive alcohol consumption.

Study design

Observational model: Case-only
Time perspective: Cross-sectional
Enrollment: 100 participants (estimated)
Patient registry: No

Interventions

Diagnostic testAbdominal Ultrasound
Diagnostic non invasive Abdomibal Ultrasound will be done to quantify hepatic steatosis

What researchers measure

Primary outcomes

waist circumference
by using a flexible non-stretchable measuring tape by identifying measurement point midway between the lower margin of last palpable rib and the top of iliac crest.
Time frame: 4 months

Study locations

1 site

Sohag university Hospital
Sohag, Egypt
- Magdy M Amin, professor · Contact

References and documents

Publications

Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13. PubMed 37700494 ↗
Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of Obesity in Adults: Latest Trends. Curr Obes Rep. 2018 Dec;7(4):276-288. doi: 10.1007/s13679-018-0317-8. PubMed 30155850 ↗
Stefan N, Schick F, Haring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017 Aug 1;26(2):292-300. doi: 10.1016/j.cmet.2017.07.008. PubMed 28768170 ↗
Chan WK, Treeprasertsuk S, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Fan JG, Song MJ, Yoon SK, Dan YY, Lesmana L, Ho KY, Goh KL, Wong VW. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018 Mar;47(6):816-825. doi: 10.1111/apt.14506. Epub 2018 Jan 14. PubMed 29333610 ↗

Individual participant data

Plan to share: Undecided

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Aug 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06536933
Lead sponsor: Sohag University
Responsible party: Hossam Eldin Hamdy Hamed (Resident-Internal Medicine department-sohag hospital university, Sohag University) — Principal investigator
First posted: Aug 5, 2024
Start date: Sep 1, 2024 (estimated)
Primary completion: Dec 31, 2024 (estimated)
Completion: Dec 31, 2024 (estimated)
Last update: Aug 5, 2024

Study contacts

Hossam Eldin H H, resident

Contact

hossamhamdy@med.sohag.edu.eg

01020678907

Ali T A, professor

Contact

01005871047

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sohag University →

Start the discussion